Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers in ACS, Pneumonia, and COPD Patients Receiving Influenza Vaccination
NCT07604103Phase 3Recruiting
- Sponsor
- Brawijaya University
- Start
- Jan 2026
- Primary completion
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of influenza vaccine in influenza (2 arms), sponsored by Brawijaya University. Primary endpoint: Levels of Inflammatory Biomarkers (GDF-15, MR proADM, and Presepsin) at 30 days. Started Jan 2026; status: recruiting.
02
Drugs
influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07604103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604103.